Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Evofem Biosciences, Inc. CEO Saundra Pelletier.

Traders News Source Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the shelf life of Phexxi® (lactic acid, citric acid, potassium bitartrate) from three to four years. "The FDA's approval to extend Phexxi's shelf life to four years speaks not only to the safety of our ingredients but also to the exceptional standards applied in the manufacturing of Phexxi," said Saundra Pelletier, Chief Executive Officer at Evofem.

US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering. Evofem says the company intends to use the net proceeds from the offering for the continuation of commercialization activities.

Why Evofem Biosciences Shares Are Getting Hammered Today

SAN DIEGO , May 20, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71,000,000 shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $0.75, less underwriting discounts and commissions, and each pre-funded warrant and accompanying common warrant are being offered at a combined public offering price of $0.749, less underwriting discounts and commissions.

Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering

SAN DIEGO , May 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common stock to certain investors) and warrants to purchase shares of its common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Evofem Biosciences Announces Proposed Public Offering

SAN DIEGO , May 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has selected Bora Pharmaceuticals Services Inc. (Bora) Canada as Evofem's new contract manufacturing organization (CMO). Bora will eventually manufacture Phexxi® (lactic acid, citric acid, and potassium bitartrate) for markets worldwide.

Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®

5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General Population The Post hoc Analysis will be Presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in San Diego, CA on May 7, 2022 SAN DIEGO , May 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi® (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population. Dr. Bassem Maximos, the lead author of the poster will present this new data set at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting on Saturday, May 7, 2022.

Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial

SAN DIEGO , May 5, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at the annual meeting of the Company held on May 4, 2022. The reverse stock split will take effect at the close of trading on the Nasdaq Capital Market, or 4:00 p.m.

Evofem Biosciences Announces 1-for-15 Reverse Stock Split

Evofem Biosciences, Inc. (NASDAQ:EVFM ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier - Chief Executive Officer, President and Executive Director Jay File - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Stacy Lee - Stifel Yale Jen - Laidlaw Ram Selvaraju - H.C. Wainwright Operator Greetings, and welcome to the Evofem Biosciences' First Quarter of 2022 Financial Results Call.

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2022 Results - Earnings Call Transcript

-- Double digit growth in net revenues over Q4 2021 -- -- Reduced selling and marketing costs 49% and total operating expense 19% vs. Q4 2021 -- -- Decreased loss from operations for the third consecutive quarter -- -- On track to report top-line Phase 3 data for the prevention of chlamydia and gonorrhea in 2H 2022 -- -- Conference call scheduled for 4:30 p.m.

Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

Evofem Anticipates Greater Numbers of Phexxi® (lactic acid, citric acid, potassium bitartrate) Prescriptions Filled as a Result of VitaCare Agreement New Agreement Provides More Efficient Patient Follow-Up Practices for Women Prescribed Phexxi through VitaCare Prescription Services with Enhanced "White Glove" Support Services SAN DIEGO , April 27, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has entered into a new agreement with VitaCare Prescription Services, a wholly-owned subsidiary of GoodRx, to provide enhanced "white glove" support services to women prescribed Phexxi® (lactic acid, citric acid, potassium bitartrate) who choose to use VitaCare. Women or their health care provider can choose to have a Phexxi prescription sent to VitaCare for fulfillment, and VitaCare will help the patient understand coverage, identify available savings opportunities, and facilitate communication between the health care provider and payor.

Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting. The poster presentation details the characterization of women who experienced urinary tract infections (UTIs) during the AMPOWER Study.

Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting

-- Conference Call Scheduled for 4:30 p.m. ET – SAN DIEGO , April 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022 as follows: Date: Wednesday, May 4, 2022 Time: 4:30 p.m.

Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022

Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate) SAN DIEGO, April 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem, Karina will oversee the company's business development, product and pipeline portfolios, new business ventures, and the advancement of access partnerships around the world.

Evofem Announces Karina Fedasz as Company's New Head of Business Development

Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of Evofem Common Stock before May 4, 2022, with Compliance by May 20, 2022 SAN DIEGO , April 7, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) ("Evofem" and the "Company"), a commercial-stage biopharmaceutical company, today announced the Nasdaq Hearings Panel (the "Panel") has granted Evofem's request to continue its listing on The Nasdaq Stock Market ("Nasdaq"), pending the outcome of the stockholder vote on the Company's reverse stock split proposal scheduled to take place at its annual general meeting on May 4, 2022. "We appreciate the Panel's decision to continue listing Evofem's common stock on Nasdaq," said Saundra Pelletier, Chief Executive Officer of Evofem.

Nasdaq Accepts Evofem Plan to Regain Listing Compliance

Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk Reduction in Neisseria Gonorrhoeae (gonorrhea) using EVO100 (investigational name for Phexxi® (lactic acid, citric acid, and potassium bitartrate)) Compared to Placebo AMPREVENCE Also Incorporated Direct Patient Health Outcomes Related to Sexual Satisfaction Positive AMPREVENCE Data Serve as the Foundation for the Ongoing, Confirmatory and Registrational Phase 3 EVOGUARD Trial Investigating EVO100 to Prevent Chlamydia and Gonorrhea in Women Topline Data from Phase 3 EVOGUARD Trial Expected in the Second Half of 2022 SAN DIEGO , March 31, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today presented data at the Academy of Managed Care Pharmacy (AMCP) annual meeting showing EVO100 (the investigational name for Phexxi®) provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product. The results are based on Evofem's Phase 2B/3 AMPREVENCE clinical trial.

Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting

SAN DIEGO, March 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has completed enrollment in EVOGUARD, the registrational Phase 3 clinical trial evaluating EVO100 (the investigational name for Phexxi® (lactic acid, citric acid, potassium bitartrate)) for two potential new indications: the prevention of chlamydia infection in women and the prevention of urogenital gonorrhea infection in women. The clinical trial design initially called for an enrollment of 1730 participants.

Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

Evofem Biosciences' (EVFM) CEO Saundra Pelletier on Q4 2021 Results - Earnings Call Transcript

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2021. "In our first full year as a commercial company Evofem delivered strong growth, capped by an exceptional fourth quarter," said Saundra Pelletier, Chief Executive Officer.

Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m.

Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi® (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development.  Chlamydia is the most frequently reported bacterial infection in the United States.

FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows: Date: Wednesday, February 23, 2022  Time: 4:30 p.m. ET (1:30 p.m.

Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

Ambev

New Gold

Here are three penny stocks to watch this month The post Best Penny Stocks to Buy Right Now? Check These 3 Out As January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? Check These 3 Out As January Ends

The stock price of Evofem Biosciences Inc (NASDAQ: EVFM) increased by over 20% during intraday trading today. This is why it happened.

Evofem Biosciences Stock (EVFM): Why The Price Jumped Up Today

Evofem Biosciences Inc (NASDAQ: EVFM) achieved preliminary net product sales of $3.5 million in Q4 FY21, more than double in Q3 FY21. During the quarter, 39,121 boxes of Phexxi were dispensed, up 81% from Q3.

News for Evofem Biosciences Inc Stock (EVFM)